Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.78 |
| ▸ | CA9 | Q16790 | 12/20 | 0.78 |
| ▸ | CA12 | O43570 | 9/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | RAB9A | P51151 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | CA1 | P00915 | 12/20 | 0.72 |
| ▸ | CA7 | P43166 | 5/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | CA4 | P22748 | 3/20 | 0.60 |
| ▸ | CA5A | P35218 | 4/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.56 |
| ▸ | CA6 | P23280 | 2/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8492321 | 0.94 | CA2 (0.70) | CA2CA9CA12MEN1NPC1 | |
| SCHEMBL42643 | 0.88 | CA2 (1.00) | CA2CA9CA12MEN1NPC1 | |
| SCHEMBL42659 | 0.88 | CA2 (1.00) | CA2CA9CA12MEN1NPC1 | |
| SCHEMBL6726371 | 0.85 | CA2 (0.62) | CA2CA9CA12MEN1NPC1 | |
| SCHEMBL13242579 | 0.84 | CA2 (1.00) | CA2CA9CA12MEN1NPC1 | |
| SCHEMBL6732051 | 0.82 | CA2 (0.57) | CA2CA9CA12MEN1NPC1 | |
| SCHEMBL29283437 | 0.82 | CA2 (0.67) | CA2CA9CA12MEN1NPC1 | |
| SCHEMBL6721636 | 0.81 | PTGS2 (0.69) | CA2CA9CA12MEN1NPC1 | |
| SCHEMBL28884814 | 0.81 | CA2 (1.00) | CA2CA9CA12MEN1NPC1 | |
| SCHEMBL25033772 | 0.80 | CA2 (0.64) | CA2CA9CA12MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | claimed |
| JP-10239908-A | — | — | None | — | — | JP | disclosed |
| CN-119738506-B | Method for improving quality detection of busulfan injection | 广州艾奇西医药科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119738506-A | Method for improving quality control of busulfan injection | 广州艾奇西医药科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-112262129-B | Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023154528-A1 | STEREOSELECTIVE TECHNOLOGIES FOR CHIRAL COMPOUNDS | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-17 | — | — | WO | disclosed |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023091644-A2 | HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| US-20010044553-A1 | Novel compound for color-producing composition, and recording material | CHEMIPRO KASEI KAISHA, LTD. (JP) | 2001-11-22 | — | — | US | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| JP-H10239908-A | NEGATIVELY CHARGEABLE TONER | SHIKOKU CHEM CORP | 1998-09-11 | — | — | JP | disclosed |
| US-5541186-A | ENDOTHELIN RECEPTOR INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5529999-A | SULFONAMIDOQUINOXALINE DERIVATIVE | ELI LILLY AND COMPANY (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0672662-A1 | Quinoxaline derivative used in the treatment of tumours | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5234955-A | N-phenyl-N*-substituted phenylsulfonylureas | ELI LILLY AND COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0550157-A1 | Antitumor compositions and methods of treatment | ELI LILLY AND COMPANY (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0427929-A2 | Heat-sensitive recording material | MITSUBISHI PAPER MILLS, LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
| US-3971769-A | NATURAL AND SYNTHETIC POLYAMIDES, CELLULOSE ACETATE | CROMPTON & KNOWLES CORPORATION (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044553-A1 | Novel compound for color-producing composition, and recording material | UROD, UMPS, UGT1A10 | CA2 1209/4885CA9 536/4885CA12 436/4885 |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CA2 2269/4885CA9 1912/4885CA12 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.